Wallingford, CT, United States of America

Kevin Ronald Condroski

This inventor holds 42 USPTO granted patents and 6 published patent applications, plus 4 CIPO patents and 16 EPO patents, primarily in Kinase Inhibitors. Top assignees: Array Biopharma Inc., Eli Lilly and Company, Celgene Corporation. Active years: 2009-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kevin Ronald Condroski. Retrieved from https://idiyas.com/inventor/kevin-ronald-condroski

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 6)

% Patents Active = 59.5

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 8.3

ph-index = 12

Forward Citations = 529(Granted Patents)

Location History:

Broomfield, CO (US) (2009 - 2015)
Wallingford, CT (US) (2014 - 2017)
San Diego, CA (US) (2014 - 2019)
Boulder, CO (US) (2011 - 2020)
Lafayette, CO (US) (2011 - 2024)

Company Filing History:

Eli Lilly and Company

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

FGFR3 Inhibitors

RET Kinase Inhibitors

Trk Kinase Inhibitors

Macrocyclic Compounds

Glucokinase Activators

Pyridin Derivatives

Peptide Inhibitors

Diabetes Treatments

Helminthic Infections

Cancer Treatments

GPR119 Modulators

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12338235 - Heterocyclic compounds and their use for treatment of helminthic infections and diseases (2025-06-24),

2. 12209086 - FGFR3 inhibitor compounds (2025-01-28),

3. 11970485 - RET kinase inhibitors (2024-04-30),

4. 11964968 - Compounds useful for inhibiting RET kinase (2024-04-23),

5. 11878976 - FGFR3 inhibitor compounds (2024-01-23),

6. 11697647 - RET kinase inhibitors (2023-07-11),

7. 11613533 - Compounds useful for inhibiting RET kinase (2023-03-28),

8. 11505548 - Heterocyclic compounds and their use for treatment of helminthic infections and diseases (2022-11-22),

9. 10758542 - Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors (2020-09-01),

10. 10647730 - Macrocyclic compounds as TRK kinase inhibitors (2020-05-12),

11. 10323022 - Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors (2019-06-18),

12. 10251889 - Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors (2019-04-09),

13. 9902741 - Macrocyclic compounds as TRK kinase inhibitors (2018-02-27),

14. 9878997 - Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors (2018-01-30),

15. 9840519 - Macrocyclic compounds as TRK kinase inhibitors (2017-12-12),

Title: **Kevin Ronald Condroski: Innovator in Therapeutic Compounds**

Introduction

Kevin Ronald Condroski, located in Wallingford, CT, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 39 patents. His work primarily focuses on developing innovative compounds aimed at treating various medical conditions, highlighting his role as a key inventor in the industry.

Latest Patents

Among his latest innovations are two notable patents concerning FGFR3 inhibitor compounds. These compounds are presented as valuable therapeutic options for conditions such as systemic sclerosis, pulmonary fibrosis, achondroplasia, thanatophoric dysplasia, and certain cancers. The innovative formulations provide hope for patients suffering from severe achondroplasia with developmental delay, as well as Muenke syndrome, and conditions characterized by significant fibrosis.

Career Highlights

Condroski has had a distinguished career, working with esteemed organizations such as Array Biopharma Inc. and Eli Lilly and Company. His expertise in pharmaceutical innovations has been instrumental in advancing therapeutic strategies, especially in the realm of genetic disorders and cancer treatments.

Collaborations

Throughout his career, Condroski has collaborated with talented colleagues, including Steven Wade Andrews and Yutong Jiang. These partnerships have facilitated groundbreaking research and the successful development of new therapeutic compounds, further enhancing the impact of his work in the field.

Conclusion

Kevin Ronald Condroski exemplifies the spirit of innovation within the pharmaceutical industry. Through his patented inventions and collaborative efforts, he continues to push the boundaries of medical science, aiming to improve the quality of life for patients with debilitating conditions. His contributions reflect the critical importance of inventors in addressing complex health challenges through innovative solutions.

Profile summary based on public USPTO records.